What’s Going On With Eliquis and Xarelto at FDA?
This article was originally published in RPM Report
Executive Summary
A key date was removed from FDA’s tentative advisory committee calendar. But a panel is still expected to review BMS’s anti-clotting agent Eliquis and a new indication for J&J’s Xarelto in ACS.